To identify potential microRNA (miRNA) links between Smad3, a mediator of TGF-b (transforming growth factor-b) signaling, and E-cadherin, we characterized the miRNA profiles of two gastric cancer cell lines: SNU484-LPCX, which does not express Smad3, and SNU484-Smad3, in which Smad3 is overexpressed. We found that among differentially expressed miRNAs, miR-200 family members are overexpressed in SNU484-Smad3 cells. Subsequent studies, including analysis of the effects of silencing Smad3 in SNU484-Smad3 cells and a luciferase reporter assay, revealed that Smad3 directly binds to a Smad-binding element located in the promoter region of miR-200b/a, where it functions as a transcriptional activator. TGF-b did not affect the regulatory role of Smad3 in transcription of miR-200 and expression of epithelial-mesenchymal transition markers. We conclude that Smad3 regulates, at the transcriptional level, miR-200 family members, which themselves regulate ZEB1 and ZEB2, known transcriptional repressors of E-cadherin, at the posttranscriptional level in a TGF-b-independent manner. This represents a novel link between Smad3 and posttranscriptional regulation by miRNAs in epithelial-mesenchymal transition in gastric cancer cells.
Introduction
Transforming growth factor-b (TGF-b) signaling has diverse roles in cell growth, differentiation, apoptosis and immune systems (Massague and Chen, 2000; Schmierer and Hill, 2007) . In the early stage of carcinogenesis, it acts as a strong tumor suppressor by arresting cell growth, maintaining genomic stability and inducing apoptosis (Roberts and Wakefield, 2003; Bierie and Moses, 2006) . In contrast, during the later stages of carcinogenesis, it can promote tumor growth by regulating angiogenesis, epithelial-mesenchymal transition (EMT), cell survival and immunosuppression (Elliott and Blobe, 2005) .
Alterations or mutations in TGF-b-signaling molecules have been strongly associated with various types of human tumors, including gastric, colon, breast and prostate cancers (Park et al., 1994; Hahm et al., 1999; Kim et al., 2006) . Defects in TGF-b receptor II have been linked with the resistance of tumor cells to the growth-inhibitory effects of TGF-b Parsons et al., 1995) . The Smads, which are mediators of TGF-b signaling, have also been shown to be mutated or deleted in tumors. Smad4 was originally identified as a tumor suppressor gene (originally named deleted in pancreatic cancer locus 4) that is deleted in pancreatic cancer (Hahn et al., 1996) . Smad4 mutations have also been identified in colorectal cancers (Calonge and Massague, 1999; Fink et al., 2001) . Elsewhere, specific loss of Smad4 in T cells in mice results in the spontaneous development of epithelial cancer throughout the gastrointestinal tract (Kim et al., 2006) . Smad2 has also been found to be mutated at very low frequency in colorectal and lung cancers (Takagi et al., 1998; Yanagisawa et al., 2000) . In case of Smad3, 37.5% of human gastric cancer tissues showed no or low expression of Smad3 (Han et al., 2004) . Recovery of Smad3 signaling blocked tumorigenicity in mice, indicating that Smad3 has a role in tumor suppression in the early stages of gastric tumorigenesis.
MicroRNAs (miRNAs) are small 21-23 nucleotides noncoding RNAs that regulate gene expression at the posttranscriptional level through target mRNA degradation or translational repression (Ambros, 2003; Bartel, 2004) . To date, 677 miRNAs have been identified in humans, each of which regulates about 200 target genes. Collectively they cover one third of all human genes. Most importantly, miRNAs have been closely linked with tumorigenesis as a result of their regulation of oncogenes and tumor suppressor genes (Ma et al., 2007; Ventura and Jacks, 2009; Levy et al., 2010) . The results of large-scale miRNA expression profiling of human cancers suggest that miRNAs can be used as diagnostic and prognostic markers for many cancer types (Lu et al., 2005; Schetter et al., 2008) . miRNAs have been shown to be promoters and suppressors of metastasis in various model systems (Huang et al., 2008; Ma and Weinberg, 2008; Tavazoie et al., 2008) . Recently, several groups reported that miR-200 family members regulate EMT by targeting the E-cadherin transcriptional repressors ZEB1 (also known as dEF1) and ZEB2 (also known as SIP1) (Gregory et al., 2008; Korpal et al., 2008; Park et al., 2008) . During EMT, miR-200 family members are markedly downregulated and E-cadherin expression decreases. Conversely, ectopic introduction of miR-200 suppresses the expression of ZEB1 and ZEB2, but induces E-cadherin expression. In this way, the miR-200 family regulates important steps in tumor progression and metastasis.
Previously, Han et al. (2004) showed that the introduction of Smad3 into a human gastric cancer cell line that does not express Smad3 restores TGF-b responsiveness and E-cadherin expression. In the present study, we aimed to profile and characterize miRNAs from the same human gastric cancer cell lines (SNU484-LPCX and SNU484-Smad3) to identify potential miRNA links between Smad3 and E-cadherin.
Results

Characterization of EMT markers in SNU484-LPCX and SNU484-Smad3 cells
We compared two gastric cancer cell lines: SNU484-LPCX, which does not express Smad3, and SNU484-Smad3, in which Smad3 is overexpressed, to examine the role of Smad3 in EMT process (Han et al., 2004) . Smad2 was expressed in both cell lines, but Smad3 protein and mRNA expression were detected only in SNU484-Smad3 cells (Figures 1a and b) . To confirm whether TGF-b signaling pathway is restored by introducing ectopic Smad3, the phosphorylation status of Smad3 was measured after treating SNU484-Smad3 cells with TGF-b for 1 h. As illustrated in Supplementary Figure 1A , TGF-b treatment induced the C-terminal phosphorylation of Smad3, which was blocked by co-treatment of SB431542, a TGF-b type I receptor inhibitor.
As for EMT markers, epithelial cell markers such as E-cadherin and ZO-1 are upregulated in SNU484-Smad3 cells, whereas mesenchymal cell markers such as Ncadherin and Vimentin are downregulated (Figures 1c-e) . E-cadherin is observed at the cell membrane as punctuated spots. ZO-1 is also observed at the cell borders, but most of it is observed throughout the cytoplasm. The treatment of cells with TGF-b or SB431542 has negligible influence on the expression levels of E-cadherin and N-cadherin (Supplementary Figures 1B-D) . These findings indicate that the expression of EMT markers in these cell lines is not dependent on TGF-b signaling pathway, but on the presence of Smad3.
As E-cadherin is downregulated in many cancers through promoter methylation (Wheeler et al., 2001; Humar et al., 2009) , we determined the methylation status of the gene encoding E-cadherin by methylationspecific PCR. No methylation in the promoter region of E-cadherin was detected either in SNU484-LPCX or SNU484-Smad3 cells (Supplementary Figure 2) , indicating that E-cadherin expression is regulated at the transcriptional or posttranscriptional level.
Sequencing and annotation of small RNAs
To identify miRNAs involved in Smad3-dependent EMT, we compared the miRNA expression profiles of SNU484-LPCX with those of SNU484-Smad3 cells, which were determined by massive parallel sequencing. The total number of sequence reads from SNU484-LPCX and SNU484-Smad3 cells were 5 317 174 and 5 512 917, respectively (GEO accession number: GSE27977). Filtering out low-quality short reads and poly-A reads, and trimming 3 0 and 5 0 adapter sequences, left 4 001 324 and 4 594 205 reads from the SNU484-LPCX and SNU484-Smad3 samples, respectively, which were used for genomic alignment (mapping) (Supplementary Table 1 ). In total, 3 209 549 and 3 416 835 mapped reads were further classified into different categories, including miRNAs, other noncoding RNAs, mRNAs, genomic repeats and unclassified species (Supplementary Figure 3) .
Differential expression of known miRNAs
Among the 750 known human miRNAs registered in mirTools , 387 and 311 miRNAs were expressed in SNU484-LPCX and SNU484-Smad3 cells, respectively. Known miRNAs showed a very broad range of expression from zero to tens of thousands of sequence reads. We found that the ten most abundant known miRNAs accounted for 66.5% and 87% of all miRNA-derived sequence reads in the SNU484-LPCX and SNU484-Smad3 libraries, respectively. Table 1 summarizes the 20 miRNAs that show the highest significant differences in the total number of sequence reads (Po0.00001). The miRNA expression profiles of the two cell lines are shown in Supplementary Table 1.
Validation of differentially expressed miRNAs
We performed miRNA-specific quantitative reverse transcriptase PCR (qRT-PCR) to validate the differences in miRNA expression. As shown in Figure 2a , the expression levels of miR-200a, miR-200c and miR302a* were significantly upregulated in SNU484-Smad3 cells, whereas miR-214, miR-363 and miR-598 were downregulated. These findings corroborate the results of the miRNA sequencing analysis.
Expression levels of miRNA were further confirmed by northern blotting using miRNA-specific probes. As shown in Figure 2b , the expression levels of miR-200 family members were markedly elevated in SNU484-Smad3 cells, whereas that of miR-363 was almost undetectable.
To examine the effect of TGF-b signaling on miRNA expression, cells were treated with TGF-b (5 ng/ml) in the presence or absence of SB431542 (2 mM) for 24 h, and miRNA levels were measured using miRNA-specific qRT-PCR (Supplementary Figure 4) . As in EMT markers, the treatment of cells with TGF-b or SB431542 has negligible influence on the expression levels of miRNA-200 members, indicating that the expression of miRNA-200 family is not dependent on TGF-b signaling pathway, but on the presence of Smad3.
Silencing of Smad3 in SNU484-Smad3 cells
To further investigate potential links between Smad3 and miRNA expression, we silenced Smad3 in SNU484-Smad3 cells using short interfering RNAs (siRNAs). As shown in Figure 3a , transfection of scramble siRNAs did not affect the expression of Smad3, whereas three different Smad3-specific siRNAs suppressed Smad3 expression. Silencing of Smad3 in SNU484-Smad3 cells reduced the expression of E-cadherin, but increased that of N-cadherin (Figures 3b and c) . Expression of E-cadherin, N-cadherin, ZO-1, F-actin and Smad3 was confirmed by immunofluorescence confocal microscopy. Cells were fixed and stained with antibodies against E-cadherin (green), N-cadherin (green), ZO-1 (green) and Smad3 (red). Expression of F-actin, which is a mesenchymal marker, was confirmed by staining with rhodamine phalloidin (red). Cell nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (blue). Scale bars: 20 mm.
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Regulation of the miR-200 promoter by Smad3
Previous reports showed that miR-200 family members were downregulated in many tumors, including breast, pancreatic and bladder cancers because of hypermethylation of the miR-200 promoter Neves et al., 2010; Vrba et al., 2010; Wiklund et al., 2011) . To test whether the downregulation of miR-200 family members in SNU484-LPCX cells resulted from miR-200 promoter hypermethylation, we treated SNU484-LPCX cells with 5-aza-2 0 -deoxycytidine. 5-aza-2 0 -deoxycytidine is an irreversible inhibitor of maintenance DNA methyltransferase, which is an enzyme that transfers methyl groups to newly synthesized DNA strands (Sen et al., 2010) . Treatment with 5-aza-2 0 -deoxycytidine for 4 days did not increase the expression of miR-200 family members in SNU484-LPCX cells, indicating that promoter hypermethylation is not involved in the downregulation of miR-200 family member expression in SNU484-LPCX cells (Supplementary Figure 7) .
As our data indicate that miR-200 family members are regulated by Smad3, we performed a reporter assay to confirm their transcriptional regulation by Smad3. A 1.4-kb sequence upstream of the miR-200b/a gene, which contains five potential Smad-binding elements, was cloned into a pGL3 reporter vector. To functionally validate the five potential Smad-binding elements in this 1.4 kb sequence, five serial deletion constructs were generated ( Figure 4a ). As illustrated in Figure 4b , the Smad3-binding site is located in the À745 to À645 bp region. Overexpression of Smad2 did not affect luciferase activity, indicating that the reporter was specific for Smad3 binding. We also introduced mutations in two Smad-binding elements located between À745 and À645 bp to identify the SBE that has the most important role in Smad3 binding ( Figure 4c ). As shown in Figure 4d , introduction of a mutation into the SBE between À657 and À653 bp significantly reduced relative luciferase activity (Po0.00005), which implies that it has a central role in Smad3 binding. To understand the role of TGF-b in regulating miR-200 transcription, we performed a reporter assay in the presence or absence of a TGF-b type I receptor inhibitor (Supplementary Figure 8 ). The promoter activity of miR-200 was slightly increased by TGF-b in Smad3-transfected cells, but not significant (P40.5). SB431542 could not block the overexpressed Smad3 effects on the miR-200 promoter as expected. 
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Discussion
The question addressed by the present study was whether an miRNA link exists between Smad3 and E-cadherin expression. To address this question, we sequenced miRNAs from the SNU484-LPCX and SNU484-Smad3 cell lines, and subsequently performed validation analyses. The main finding of the present study is that Smad3 regulates E-cadherin expression through miR-200 family members, and ZEB1 and ZEB2. According to our findings, Smad3 regulates, at the transcriptional level, miR-200 family members, which themselves regulate ZEB1 and ZEB2, transcriptional repressors of E-cadherin, at the posttranscriptional level ( Figure 5 ). As previously reported, the TGF-b signaling pathway, in which Smad3 functions as an important mediator, has dual functionality, suppressing tumor growth during the early stages of cancer, but acting as a promoter of EMT during the later stage of cancer (Roberts and (2010) showed that the restoration of Smad4 expression in SW480 cells led to their reversion from a mesenchymal-like phenotype to an epithelial phenotype, which corroborates our observations. Although ectopic Smad3 induces the expression of E-cadherin and ZO-1 in SNU484-Smad3 cells, it does not lead to the formation of functional tight junction, which is a marker of epithelial cell (Figure 1e ). These results may explain why Smad3 shows different functions in present study compared with TGF-b-induced EMT process.
By introducing ectopic Smad3, TGF-b signaling pathway was restored in SNU484-Smad3 cells. TGF-b signaling, however, did not affect the expression of Figure 4) . These findings suggest two things: (1) Endogenous TGF-b signaling is not involved in the upregulation of EMT markers in SNU484-Smad3 cells; (2) the overexpressed Smad3 itself regulates the expression of miRNA genes, some of which mediate mesenchymal-epithelial transition (MET) in a TGF-bindependent way. This observation reconciles with previous reports that Smad3 regulates target genes through a TGF-b-independent pathway (Inoue et al., 2009; Yang et al., 2009; Chung et al., 2010) . In most cases, the transcriptional regulation of miRNA is not fully understood. Corcoran et al. (2009) recently described putative transcription start sites in miRNA promoters identified by chromatin immunoprecipitation-on-chip analysis of RNA polymerase IIbinding sites. According to the authors, the locations of transcription start sites vary from 0 to 40 kb upstream of miRNA genes. Furthermore, the transcription start sites of the miR-200b/a and miR-200c clusters have been suggested to be located 8763 and 1976 bp upstream of their respective cluster (Corcoran et al., 2009) . In the present study, we showed that Smad3, when acting as a transcriptional activator, binds to a more proximal region (between À657 and À653 bp upstream) of miR-200b/a promoter (Figure 4 ).
In conclusion, our findings strongly suggest that Smad3 modulates EMT by regulating miR-200 clusters in a TGF-b-independent manner. MiRNAs that regulate multiple target genes simultaneously can provide an effective link between a master regulator gene such as Smad3 and a complex biological process such as EMT. In the same context, our findings also suggest that miRNAs may be good therapeutic targets for the control of cancer metastasis.
Materials and methods
Cell culture and reagents SNU484-LPCX, which does not express Smad3, and SNU484-Smad3, which stably expresses flag-tagged Smad3, were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, miR-200-mediated regulation of E-cadherin by Smad3 S-M Ahn et al CA, USA) supplemented with 10% fetal bovine serum and 1% streptomycin/penicillin (Invitrogen) in a 5% CO 2 atmosphere at 37 1C, as described in a previous report (Han et al., 2004) . Stable cell lines were maintained in puromycin (400 ng/ml). The human hepatoma cell line, HepG2, was obtained from the ATCC (Manassas, VA, USA) and grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum and 1% streptomycin/penicillin. Recombinant human TGF-b was from R&D Systems (Minneapolis, MN, USA). An anti-Smad2/3 and phosho-Smad3 antibody were purchased from Cell Signaling (Beverly, MA, USA); antibodies against Flag (M2), Vimentin (Catalogue no. 6630), and b-actin (Clone AC-15) and SB431542 were obtained from Sigma (St Louis, MO, USA); and antibodies against E-cadherin (Catalogue no. 610182) and N-cadherin (Cat no. 610920) were acquired from BD Biosciences (San Jose, CA, USA). ZO-1 (Cat no. 339100) antibody and rhodamine phalloidin (Cat. no. R415) were obtained from Invitrogen. Rabbit anti-ZEB1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for detecting endogenous protein.
Western blotting
Total cell extracts were prepared by harvesting SNU484 and HepG2 cells in a lysis buffer containing 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM EDTA, phosphatase inhibitors (Sigma) and a protease cocktail (Roche, Indianapolis, IN, USA). After 10 min on ice, cell debris was removed by centrifugation at 10 000 g for 10 min. Protein concentrations were determined by the BCA (bicinchoninic acid) method (Pierce, Rockford, IL, USA) using bovine serum albumin as a control. Next, proteins were separated by SDS-PAGE (SDS-polyacrylamide gel electrophoresis) and then transferred onto polyvinylidene difluoride membranes, which were treated with the appropriate primary antibodies. Antibody-bound proteins were detected by a chemiluminescence method according to the manufacturer's protocol (Pierce).
Preparation of a small RNA library A small RNA library was prepared using a small RNA preparation kit according to the manufacturer's instructions (Illumina, San Diego, CA, USA). Briefly, 10 mg of total RNA was size-fractionated on a 15% TBE-urea PAGE gel (Invitrogen), and an 18-30-bp band was excised from the fractionation gel and mashed. RNA was eluted from the mashed gel debris, filtered using a Spin-X cellulose filter (Sigma), and precipitated. An SRA 5 0 adaptor was ligated to the small RNA with T4 RNA ligase, and the ligated RNA then size-fractionated on a 15% TBE-urea PAGE gel. A 40-60-bp band was excised. SRA 3 0 adaptors (5 0 -UCGUAUGCCGU CUUCUGCUUGUidT-3 0 ) were ligated to small RNAs with T4 RNA ligase, and the ligated 3 0 adaptor RNA was then fractionated on a 10% TBE-urea gel (Invitrogen). A 70-90-bp band was excised. The small RNA was converted to single-stranded cDNA using SuperScript II (Invitrogen) and SRA RT primers (5 0 -CAAGCAGAAGACGGCATAC GA-3 0 ). The cDNA was amplified using Illumina's PCR primer set (5 0 -CAAGCAGAAGACGGCATACGA-3 0 and 5 0 -AATG ATACGGCGACCACCGACAGGTTCAGAGTTCTACAGT CCGA-3 0 ). The following PCR conditions were used: 98 1C for 30 s; 18 cycles at 98 1C for 10 s, 60 1C for 30 s and 72 1C for 15 s; and a final extension at 72 1C for 10 min. The single-stranded cDNA was fractionated on a 6% TBE gel. An approximately 92-bp band was excised from the size-fractionation gel and the resulting slurry was filtered using a Spin-X filter (Sigma). The resulting cDNA was precipitated, resuspended and sequenced. To validate the library, cDNA concentrations and 260/280 ratios were measured using a NanoDrop spectrophotometer (ThermoFisher, Wilmington, DE, USA).
Massively parallel sequencing and data analysis A small RNA library was sequenced using an Illumina 1G Genome Analyzer according to the manufacturer's instructions. Analysis of the sequencing data was performed using mirTools (Institute of Genomic Medicine, Wenzhou, China) with default parameters .
Real-time PCR analysis of miRNA expression Total RNA was reverse-transcribed using a TaqMan Micro-RNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) and subjected to real-time PCR using TaqMan MicroRNA assay kits (Applied Biosystems). Reactions were performed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). All reactions were run in triplicate, and data were normalized to the expression level of RNU6B. Data were analyzed using the comparative C t method.
Northern blotting of miRNA Twenty micrograms of total RNA was separated on a 15% polyacrylamide, 7 M urea gel, and transferred to a Hybond-N þ membrane (GE Healthcare, Piscataway, NJ, USA). The membrane was UV-cross-linked and hybridized with isotopelabeled probes at 37 1C for 16 h. The sequences of the probes are listed in Supplementary Table 2. Probes were labeled using T4 PNK kinase and [g-32 P] ATP (Perkin Elmer, Boston, MA, USA). Unlabeled probes were removed using a G-25 column (GE Healthcare). Real-time qPCR analysis of mRNA expression Total RNA was isolated from cultured cells using either TRIzol (Invitrogen) or QIAzol (Qiagen, Valencia, CA, USA). Two micrograms of total RNA was treated with RNase-free DNase (Roche), and then reverse-transcribed using random hexamers and SuperScript II (Invitrogen). Gene-specific primers were designed using Primer Express Software (Perkin Elmer), and real-time qPCR was performed using an ABI Prism 7900HT Sequence Detection System and SYBR Green chemistry, as previously described (Kurrasch et al., 2004) . Data were analyzed using the comparative C t method with cyclophilin as an invariant control gene. All samples were analyzed in triplicate and data were expressed as the mean ± s.d. Statistical analyses for qRT-PCR results were carried out using a two-tailed t-test. Primer sequences are listed in Supplementary Table 3 .
Silencing of endogenous human Smad3
To silence endogenous human Smad3, we used the Stealth RNAi knockdown system (Invitrogen). Stealth RNAi-negative control duplexes (Catalogue. no. 12935) were used as scramble siRNAs. The siRNAs were transfected into cells using Lipofectamine RNAiMAX, according to the manufacturer's protocol (Invitrogen). After incubation for 48 h, cells were lysed and RNA or protein was extracted.
Immunofluorescence microscopy SNU484 cells were seeded into 8-well plates, fixed with 4% (v/v) paraformaldehyde in phosphate-buffered saline for 20 min at room temperature, and then permeabilized with 0.5% Triton X-100 in phosphate-buffered saline. Next, the cells were stained with primary antibody and subsequently with either an Alexa Fluor 488-conjugated goat anti-mouse secondary antibody or an Alexa Fluor 594-conjugated goat anti-rabbit secondary antibody (Invitrogen). Cell nuclei were stained with 4 0 ,6-diamidino-2-phenylindole. After staining, fluorescence images were acquired using an LSM700 confocal microscope (Carl Zeiss, Thornwood, NY, USA).
Luciferase reporter assay
All transfections were performed using Lipofectamine Plus reagent according to the manufacturer's instructions (Invitrogen). Luciferase activity was measured 48 h posttransfection with a luciferase assay substrate (Promega, Madison, WI, USA) using a Victor microplate luminometer (PerkinElmer) and normalized to b-galactosidase activity. All assays were performed in triplicate and data expressed as the mean of three independent experiments.
Site-directed mutagenesis Smad-binding elements in the miR-200b/a promoter at approximate positions À675 to À671 (SBE1) and À657 to À653 (SBE2) were mutated by replacing the GTCTG sequences with ATCCG sequences. The mutants were generated using an EZchange Site-Directed Mutagenesis Kit according to the manufacturer's instructions (Enzynomics, Daejeon, Korea).
